Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.
Public ClinicalTrials.gov record NCT01770379. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety, Tolerability and Usability up to 5 Years in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFα Agents
Study identification
- NCT ID
- NCT01770379
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 242 participants
Conditions and interventions
Conditions
Interventions
- Secukinumab (AIN457) Biological
- Placebo Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2012
- Primary completion
- Apr 30, 2015
- Completion
- Apr 30, 2015
- Last update posted
- Jul 20, 2016
2012 – 2015
United States locations
- U.S. sites
- 25
- U.S. states
- 15
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Peoria | Arizona | 85381 | — |
| Novartis Investigative Site | Santa Monica | California | 90404 | — |
| Novartis Investigative Site | Upland | California | 91786 | — |
| Novartis Investigative Site | Miami | Florida | 33135 | — |
| Novartis Investigative Site | Pembroke Pines | Florida | 33026 | — |
| Novartis Investigative Site | Zephyrhills | Florida | 33542 | — |
| Novartis Investigative Site | Cumberland | Maryland | 21502 | — |
| Novartis Investigative Site | Edina | Minnesota | 55435 | — |
| Novartis Investigative Site | Tupelo | Mississippi | 38801 | — |
| Novartis Investigative Site | Lees Summit | Missouri | 64086 | — |
| Novartis Investigative Site | St Louis | Missouri | 63128 | — |
| Novartis Investigative Site | Reno | Nevada | 89502 | — |
| Novartis Investigative Site | Albuquerque | New Mexico | 87102 | — |
| Novartis Investigative Site | Zanesville | Ohio | 43701 | — |
| Novartis Investigative Site | Oklahoma City | Oklahoma | 73103 | — |
| Novartis Investigative Site | Oklahoma City | Oklahoma | 73134 | — |
| Novartis Investigative Site | North Charleston | South Carolina | 29406 | — |
| Novartis Investigative Site | Rapid City | South Dakota | 57701 | — |
| Novartis Investigative Site | Jackson | Tennessee | 38305 | — |
| Novartis Investigative Site | Nashville | Tennessee | 37203-1424 | — |
| Novartis Investigative Site | Amarillo | Texas | 79124 | — |
| Novartis Investigative Site | Benbrook | Texas | 76126 | — |
| Novartis Investigative Site | Houston | Texas | 77005 | — |
| Novartis Investigative Site | Houston | Texas | 77034 | — |
| Novartis Investigative Site | Mesquite | Texas | 75150 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01770379, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 20, 2016 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01770379 live on ClinicalTrials.gov.